Cardiovascular Revascularization Medicine
ClinicalProcedural and thirty-day outcomes following transfemoral implantation of the fully repositionable and retrievable Lotus valve without routine pre-dilatation in a consecutive patient cohort: a single-center experience☆
Introduction
Transcatheter aortic valve implantation (TAVI) is now the accepted treatment option for patients deemed to be inoperable or of high surgical risk presenting with severe symptomatic aortic stenosis [1], [2], [3]. A number of randomised trials have demonstrated efficacy and mortality benefit over medical therapy [4] and conventional surgery in high-risk patients [5]. With increasing institutional and operator experience combined with technological advancements, there has been an interest in the applicability of TAVI in the management of intermediate [6], [7] and even low risk [8] patients. Additionally, in a bid to further simplify the procedure, there has been a decreasing trend in the proportion of patients undergoing pre-dilatation prior to valve implantation [9]. This approach is potentially also associated with benefits of shorter procedure times, reduced radiation and contrast use and the avoidance of balloon aortic valvuloplasty (BAV) related complications (e.g. cerebrovascular events, conduction disturbances, severe aortic regurgitation) [10], [11].
First generation devices however were limited by vascular complications, paravalvular leak, stroke, renal impairment and the requirement of permanent pacemaker implantation [12]. Newer generation devices have therefore been developed with improvements in both the delivery systems and prostheses to overcome these and is particularly important when considering the treatment of lower-risk, younger patients. The Lotus valve (Boston Scientific, Natick, MA, USA) is a second-generation device that is fully repositionable and retrievable with an adaptive seal to reduce the occurrence of paravalvular leak. The use of this valve has been demonstrated to be safe and efficacious in the setting of clinical trials [13], [14], single- [15] and multi-centre [16], [17] registries. However, these were all limited to specific pre-selected groups that were also predominantly treated with pre-dilatation prior to valve implantation that may not be representative of an ‘all-comer’ contemporary patient cohort treated with present day techniques.
We here describe our experiences of implantation of the Lotus device as a ‘workhorse’ device in an unselected consecutive patient cohort without routine pre-dilatation.
Section snippets
Study population
All patients that underwent transfemoral TAVI for native severe symptomatic aortic stenosis at the John Radcliffe Hospital, Oxford, United Kingdom between January 2015 (first Lotus valve (Boston Scientific, Natick, MA) implant) and December 2016 were prospectively collected and retrospectively analysed. All first time transfemoral TAVI patients were treated with the Lotus device during this period (with no other device used). Patients that underwent valve-in-valve TAVI, intervention for aortic
Patient population
146 consecutive patients were treated within the study period and were included in the final analysis. Baseline demographics of the study population are summarised in Table 1. The mean age was 81.1 ± 7.4 years and 47.3% of patients were male. Seventeen patients (11.6%) presented with concomitant pulmonary hypertension and 23 patients (15.8%) had a history of previous sternotomy. Twenty patients (13.7%) had severely impaired resting left ventricular systolic function. The mean logistic EuroSCORE
Discussion
The principal findings of this study are: (1) the Lotus valve can be used safely and is efficacious in a consecutive patient ‘all-comer’ group as a ‘work-horse’ device; (2) the absence of routine pre-dilatation prior to Lotus valve implantation is associated with acceptable transvalvular haemodynamics and; (3) very low rates of (greater than mild) residual paravalvular leak; (4) permanent pacemaker implantation rates remain high although the significance of this remains uncertain.
This is the
Conclusion
The Lotus valve can be used safely and is efficacious in the management of an unselected consecutive patient cohort presenting with severe symptomatic aortic stenosis without mandatory pre-dilatation and is associated with a very low incidence of residual aortic regurgitation and acceptable transvalvular haemodynamics.
Acknowledgements
None
References (27)
- et al.
2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
J Am Coll Cardiol
(2014) - et al.
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement
J Am Coll Cardiol
(2012) - et al.
Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial
J Am Coll Cardiol
(2015) - et al.
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document
J Am Coll Cardiol
(2012) - et al.
Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study
J Am Coll Cardiol
(2014) - et al.
1-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results of the REPRISE II Study
JACC Cardiovasc intervent
(2016) - et al.
Transcatheter Aortic Valve Replacement Using the Repositionable LOTUS Valve: United Kingdom Experience
JACC Cardiovasc Interv
(2016) - et al.
Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography
J Am Soc Echocardiogr
(2003) - et al.
Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation
Am J Cardiol
(2012) - et al.
Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis
Lancet
(2016)
Increased Risk of Cerebral Embolization After Implantation of a Balloon-Expandable Aortic Valve Without Prior Balloon Valvuloplasty
JACC Cardiovasc Interv
Predictors of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement With the SAPIEN 3
JACC Cardiovasc Interv
Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry
JACC Cardiovasc Interv
Cited by (7)
Transcatheter aortic valve replacement complications: A narrative review for emergency clinicians
2022, American Journal of Emergency MedicineCitation Excerpt :A total of 142 resources were selected for inclusion in this review. Overall, TAVR is relatively safe with low periprocedural mortality rates, estimated to range between 1.1 and 4.2% [18,19]. The risk profile of individuals who ultimately undergo TAVR is typically well-defined, as most centers have a “heart team,” composed of cardiologists, cardiac surgeons, radiologists, and anesthesiologists that evaluate patients with AS prior to surgical or procedural intervention [11].
Transcatheter Aortic Valve Implantation With J-Valve: 2-Year Outcomes From a Multicenter Study
2021, Annals of Thoracic SurgeryCitation Excerpt :In our study, the 2-year the major adverse cardiovascular and cerebrovascular events rate was only 18.7%, which is much lower than that in other studies.9 In particularly, the stroke rate (0% at 30 days and 2.8% at 2 years) was much lower than those reported in most recent publications.5,10,11 This is likely due to the simplicity of J-Valve implantation and more AI patients in our study.
Device Embolization in Structural Heart Interventions: Incidence, Outcomes, and Retrieval Techniques
2019, JACC: Cardiovascular InterventionsCitation Excerpt :This occurred in the setting of severe ventricular hypertrophy and sigmoid septum and was managed percutaneously. No other DE was observed in the pivotal clinical trial and other large registries of the Lotus valve (18–20). Embolizations of THVs have also been reported during transcatheter mitral VinV and valve-in-ring (VinR) implantation procedures, and with THV implantation in severely calcified mitral annulus (21–24).
Impact of balloon predilatation in patients with reduced versus preserved ejection fraction during transcatheter aortic valve implantation
2022, Asian Cardiovascular and Thoracic AnnalsBalloon sizing for transcatheter aortic valve implantation using 3<sup>rd</sup> generation valves, does it still work?
2021, International Medical JournalUltrasound guided vascular access site management and left ventricular pacing are associated with improved outcomes in contemporary transcatheter aortic valve replacement: Insights from the OxTAVI registry
2020, Catheterization and Cardiovascular Interventions
- ☆
Disclosure Statement: All authors confirm that there are no conflicts of interest with regards to the contents of this work.